Publications by authors named "M Marcq"
Article Synopsis
- The study investigated the effects of COVID-19 lockdown restrictions on lung cancer patients, comparing outcomes from 2020 with those from the same period in 2019.
- Clinical characteristics were similar between the two groups, but 2020 patients were older and had more non-smokers.
- Despite concerns, the lockdown did not negatively affect lung cancer management or long-term survival; instead, some patients saw improved outcomes, especially non-smokers and those receiving systemic therapies.
Outside clinical trials, few data are available on the effect of long-term first-line pembrolizumab in patients with advanced non-small-cell lung cancers with ≥50% of tumor cells expressing programmed cell death ligand 1 (PD-L1). This French, multicenter study included consecutive advanced patients with non-small-cell lung cancer given first-line pembrolizumab alone between May 2017 (authorization date for this indication) and November 2019 (authorization date for pembrolizumab-chemotherapy combination). Information was collected from patients' medical files, with a local evaluation of the response and progression-free survival (PFS).
View Article and Find Full Text PDFArticle Synopsis
- A national, multicenter study analyzed the effects of first-line immunotherapy with pembrolizumab on advanced NSCLC patients, focusing on those with brain metastases, between May 2017 and November 2019.
- The study included 845 patients, with 20.8% having brain metastases; outcomes showed similar median progression-free survival and overall survival for both groups, indicating that brain metastasis did not significantly impact therapy effectiveness.
- The research identified performance status and neutrophil-to-lymphocyte ratio as key negative factors for overall survival, while brain metastasis was not independently associated with poorer outcomes.
Article Synopsis
- Antiangiogenic agents have shown to improve outcomes for non-squamous non-small-cell lung cancer (NSCLC) patients, but there's limited information on their eligibility for squamous NSCLC (SQ-NSCLC) patients.
- In a study involving 317 advanced SQ-NSCLC patients, over half were found to have ineligibility criteria for receiving antiVEGF treatment, with the most common issues including disease extension and cardiovascular conditions.
- Despite these concerns, nearly half of the participants were eligible for antiVEGF agents, suggesting that more research and development for these treatments in SQ-NSCLC should be pursued.
Background: Osimertinib, a third-generation tyrosine kinase inhibitor, is a new therapeutic option in epidermal growth factor receptor (EGFR)-mutated non-pretreated advanced non-small-cell lung cancer (NSCLC). The tumor escape mechanisms after first-line treatment with osimertinib are partially known; most of the data being obtained by analysis of circulating tumor DNA (ctDNA) from the FLAURA phase III trial.
Study Design: The MELROSE study, a French multicentric, open label, phase II trial (ClinicalTrials.